ADAR1 Capital Management, LLC
13F Reported Value
ⓘ$1.7B
incl. option notional
Equity Holdings
ⓘ$1.7B
Option Notional
ⓘ$34.7M
$12.5M puts / $22.2M calls
Holdings
310
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
ADAR1 Capital Management, LLC disclosed 310 positions worth $1.7B in its Form 13F-HR for Q1 2026 — $1.7B in common stock plus $34.7M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ABVX (Abivax S.A.) at 9.3% of the equity portfolio, followed by $PTGX and $ROIV. During the quarter the fund opened 78 new positions and exited 40 — including a new stake in $BEAM and a full exit from $RAPT. The portfolio is most concentrated in Healthcare (89.7% of disclosed assets). All figures are sourced directly from ADAR1 Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1940272.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$155.2M1,394,019 sh - 24.8#2,572
Quality
$104.8M994,119 sh - —
Quality
$91.0M3,285,906 sh - —
Quality
$66.5M2,679,010 sh - —
Quality
$49.4M75,940 sh - —
Quality
$48.2M914,699 sh - 28.0
Quality
$41.7M632,556 sh - 26.5
Quality
$41.4M1,139,331 sh EA SERIES TRUST - ALPHA ARCH 1-3
—Quality
$39.2M337,125 sh- —
Quality
$35.9M1,871,455 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| — | $155.2M | 1,394,019 | |
| 24.8#2,572 | $104.8M | 994,119 | |
| — | $91.0M | 3,285,906 | |
| — | $66.5M | 2,679,010 | |
| — | $49.4M | 75,940 | |
| — | $48.2M | 914,699 | |
| 28.0 | $41.7M | 632,556 | |
| 26.5 | $41.4M | 1,139,331 | |
| EA SERIES TRUST - ALPHA ARCH 1-3 | — | $39.2M | 337,125 |
| — | $35.9M | 1,871,455 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ADAR1 Capital Management, LLC's 310 positions.
Showing top 10 of 310 holdings.
Sector Allocation
Healthcare
$1.5B
Other
$137.7M
Financials
$18.4M
Technology
$8.2M
Consumer Discretionary
$2.1M
Industrials
$1.8M
Materials
$1.3M
Consumer Staples
$1.0M
Full Holdings — ADAR1 Capital Management, LLC (Q1 2026)
All 310 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | Abivax S.A. | $155.2M | 9.3% | -47% | — | |
| 2 | Protagonist Therapeutics, Inc | $104.8M | 6.3% | -53% | 24.8 | |
| 3 | Roivant Sciences Ltd. | $91.0M | 5.5% | -52% | — | |
| 4 | Immunovant, Inc. | $66.5M | 4.0% | -46% | — | |
| 5 | SPDR S&P 500 ETF TRUST | $49.4M | 3.0% | -31% | — | |
| 6 | Terns Pharmaceuticals, Inc. | $48.2M | 2.9% | -16% | — | |
| 7 | CYTOKINETICS INC | $41.7M | 2.5% | -41% | 28 | |
| 8 | Crinetics Pharmaceuticals, Inc. | $41.4M | 2.5% | +84% | 26.5 | |
| 9 | — | EA SERIES TRUST - ALPHA ARCH 1-3 | $39.2M | 2.4% | -50% | — |
| 10 | Denali Therapeutics Inc. | $35.9M | 2.2% | +1695% | — | |
| 11 | Beam Therapeutics Inc. | $34.5M | 2.1% | NEW | 12.1 | |
| 12 | Zai Lab Ltd | $26.8M | 1.6% | -43% | — | |
| 13 | Septerna, Inc. | $26.2M | 1.6% | -53% | 44.6 | |
| 14 | Vir Biotechnology, Inc. | $24.6M | 1.5% | NEW | 5.6 | |
| 15 | DBV Technologies S.A. | $21.2M | 1.3% | NEW | 6.1 | |
| 16 | Anteris Technologies Global Corp. | $21.0M | 1.3% | +53% | — | |
| 17 | Inspire Medical Systems, Inc. | $20.9M | 1.3% | +1251% | 46 | |
| 18 | Scholar Rock Holding Corp | $20.0M | 1.2% | +193% | — | |
| 19 | RHYTHM PHARMACEUTICALS, INC. | $18.4M | 1.1% | +106% | 30.3 | |
| 20 | Spyre Therapeutics, Inc. | $17.1M | 1.0% | +397% | — | |
| 21 | CytomX Therapeutics, Inc. | $16.0M | 1.0% | -59% | 19.1 | |
| 22 | — | PROTHENA CORP PLC - SHS | $15.4M | 0.9% | -46% | — |
| 23 | Sanofi | $15.3M | 0.9% | +150% | — | |
| 24 | Vaxcyte, Inc. | $15.1M | 0.9% | -59% | — | |
| 25 | Monopar Therapeutics | $14.5M | 0.9% | -44% | — | |
| 26 | Arbutus Biopharma Corp | $14.1M | 0.8% | -71% | — | |
| 27 | Amylyx Pharmaceuticals, Inc. | $13.9M | 0.8% | -44% | — | |
| 28 | Celldex Therapeutics, Inc. | $13.6M | 0.8% | -67% | 13.2 | |
| 29 | Taysha Gene Therapies, Inc. | $13.3M | 0.8% | -40% | 4.1 | |
| 30 | Xenon Pharmaceuticals Inc. | $13.3M | 0.8% | -44% | 12.9 | |
| 31 | SUTRO BIOPHARMA, INC. | $13.1M | 0.8% | +291% | 30.1 | |
| 32 | Revolution Medicines, Inc. | $13.0M | 0.8% | -54% | — | |
| 33 | Enliven Therapeutics, Inc. | $12.9M | 0.8% | +449% | — | |
| 34 | CG Oncology, Inc. | $12.6M | 0.8% | -64% | 28 | |
| 35 | — | SPDR SERIES TRUST - STATE STREET SPD | $12.4M | 0.8% | -50% | — |
| 36 | ESTABLISHMENT LABS HOLDINGS INC. | $12.1M | 0.7% | -38% | 26.7 | |
| 37 | Replimune Group, Inc. | $12.1M | 0.7% | -36% | — | |
| 38 | Inventiva S.A. | $12.1M | 0.7% | -60% | — | |
| 39 | IONIS PHARMACEUTICALS INC | $12.0M | 0.7% | -46% | 37.1 | |
| 40 | NEKTAR THERAPEUTICS | $11.6M | 0.7% | +12% | 10.2 | |
| 41 | Inhibikase Therapeutics, Inc. | $11.1M | 0.7% | -59% | — | |
| 42 | ARS Pharmaceuticals, Inc. | $10.9M | 0.7% | +84% | 29.7 | |
| 43 | Terns Pharmaceuticals, Inc. | $10.5M | — | NEW | — | |
| 44 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $10.3M | 0.6% | NEW | — |
| 45 | Ovid Therapeutics Inc. | $10.1M | 0.6% | -47% | 13.1 | |
| 46 | OnKure Therapeutics, Inc. | $10.1M | 0.6% | +20% | — | |
| 47 | REGENERON PHARMACEUTICALS, INC. | $9.4M | 0.6% | -50% | 75.1 | |
| 48 | MoonLake Immunotherapeutics | $8.5M | 0.5% | NEW | — | |
| 49 | Lexeo Therapeutics, Inc. | $8.4M | 0.5% | -47% | — | |
| 50 | Opus Genetics, Inc. | $8.4M | 0.5% | +2211% | — | |
| 51 | TEVA PHARMACEUTICAL INDUSTRIES LTD | $8.1M | 0.5% | -43% | — | |
| 52 | Savara Inc | $8.0M | 0.5% | -48% | — | |
| 53 | MapLight Therapeutics, Inc. | $7.6M | 0.5% | NEW | — | |
| 54 | LeonaBio, Inc. | $7.5M | 0.5% | -8% | — | |
| 55 | Equillium, Inc. | $7.5M | 0.5% | -67% | 27.2 | |
| 56 | Viking Therapeutics, Inc. | $7.4M | 0.5% | +330% | — | |
| 57 | Damora Therapeutics, Inc. | $7.2M | 0.4% | NEW | — | |
| 58 | UroGen Pharma Ltd. | $7.1M | 0.4% | +58% | — | |
| 59 | BridgeBio Pharma, Inc. | $7.0M | 0.4% | -78% | 31.7 | |
| 60 | Prime Medicine, Inc. | $6.9M | 0.4% | NEW | 11.2 | |
| 61 | — | ISHARES TR - RUSSELL 2000 ETF | $6.8M | — | -50% | — |
| 62 | VERTEX PHARMACEUTICALS INC / MA | $6.7M | 0.4% | -45% | 76.6 | |
| 63 | Korro Bio, Inc. | $6.1M | 0.4% | NEW | 5.8 | |
| 64 | Viridian Therapeutics, Inc.\DE | $6.0M | 0.4% | +97% | 30.5 | |
| 65 | DANAHER CORP /DE/ | $5.9M | 0.3% | -40% | 63.9 | |
| 66 | INSMED Inc | $5.8M | 0.3% | NEW | 29.4 | |
| 67 | Ascendis Pharma A/S | $5.7M | 0.3% | -51% | 41.5 | |
| 68 | Brighthouse Financial, Inc. | $5.7M | 0.3% | -50% | 54.9 | |
| 69 | Sarepta Therapeutics, Inc. | $5.7M | 0.3% | +354% | 41.6 | |
| 70 | Oaktree Acquisition Corp. III Life Sciences | $5.5M | 0.3% | -50% | — | |
| 71 | Perceptive Capital Solutions Corp | $5.5M | 0.3% | -79% | — | |
| 72 | Krystal Biotech, Inc. | $5.2M | 0.3% | -50% | 75.9 | |
| 73 | Acumen Pharmaceuticals, Inc. | $5.1M | 0.3% | +21% | — | |
| 74 | Invivyd, Inc. | $5.0M | 0.3% | -51% | 25.7 | |
| 75 | BridgeBio Pharma, Inc. | $4.9M | 0.3% | NEW | 31.7 | |
| 76 | — | BHAV ACQUISITION CORP - UNIT 03/18/2031 | $4.9M | 0.3% | NEW | — |
| 77 | Protara Therapeutics, Inc. | $4.9M | 0.3% | -59% | — | |
| 78 | Abivax S.A. | $4.9M | — | NEW | — | |
| 79 | — | BRIDGEBIO PHARMA INC - NOTE 1.750% 3/0 | $4.9M | 0.3% | NEW | — |
| 80 | AGIOS PHARMACEUTICALS, INC. | $4.8M | 0.3% | -63% | 26.3 | |
| 81 | ELI LILLY & Co | $4.7M | 0.3% | NEW | 89.3 | |
| 82 | Dianthus Therapeutics, Inc. /DE/ | $4.6M | 0.3% | NEW | 26.8 | |
| 83 | ARROWHEAD PHARMACEUTICALS, INC. | $4.4M | 0.3% | -40% | 74.4 | |
| 84 | BELITE BIO, INC | $4.3M | 0.3% | -66% | — | |
| 85 | Evommune, Inc. | $4.2M | 0.3% | -50% | — | |
| 86 | Mineralys Therapeutics, Inc. | $4.2M | 0.3% | -43% | — | |
| 87 | Janux Therapeutics, Inc. | $4.1M | 0.3% | -39% | 24.8 | |
| 88 | Climb Bio, Inc. | $4.1M | 0.3% | -79% | — | |
| 89 | PALISADE BIO, INC. | $4.0M | 0.2% | -44% | — | |
| 90 | American Exceptionalism Acquisition Corp. A | $3.9M | 0.2% | -50% | — | |
| 91 | SPRUCE BIOSCIENCES, INC. | $3.8M | 0.2% | -49% | — | |
| 92 | NewAmsterdam Pharma Co N.V. | $3.8M | 0.2% | -50% | — | |
| 93 | Liquidia Corp | $3.8M | — | +104% | 37.4 | |
| 94 | Zura Bio Ltd | $3.8M | 0.2% | -44% | — | |
| 95 | Arcellx, Inc. | $3.7M | 0.2% | -49% | 6.7 | |
| 96 | Contineum Therapeutics, Inc. | $3.6M | 0.2% | -50% | — | |
| 97 | BridgeBio Pharma, Inc. | $3.6M | 0.2% | NEW | 31.7 | |
| 98 | Monte Rosa Therapeutics, Inc. | $3.5M | 0.2% | -50% | 18.1 | |
| 99 | BeOne Medicines Ltd. | $3.5M | 0.2% | NEW | — | |
| 100 | TENAX THERAPEUTICS, INC. | $3.4M | 0.2% | +68% | — | |
| 101 | ArriVent BioPharma, Inc. | $3.3M | 0.2% | NEW | — | |
| 102 | PLIANT THERAPEUTICS, INC. | $3.3M | 0.2% | +1651% | — | |
| 103 | Atai Beckley N.V. | $3.2M | 0.2% | -50% | — | |
| 104 | RELMADA THERAPEUTICS, INC. | $3.1M | 0.2% | +632% | — | |
| 105 | Perspective Therapeutics, Inc. | $3.1M | 0.2% | +294% | — | |
| 106 | Corbus Pharmaceuticals Holdings, Inc. | $3.1M | 0.2% | -42% | — | |
| 107 | Eledon Pharmaceuticals, Inc. | $3.0M | 0.2% | -73% | — | |
| 108 | Pharvaris N.V. | $3.0M | 0.2% | -38% | — | |
| 109 | Apellis Pharmaceuticals, Inc. | $2.9M | 0.2% | +81% | 63.9 | |
| 110 | Edgewise Therapeutics, Inc. | $2.9M | 0.2% | -50% | — | |
| 111 | PepGen Inc. | $2.8M | 0.2% | +2082% | — | |
| 112 | CAPRICOR THERAPEUTICS, INC. | $2.8M | 0.2% | NEW | — | |
| 113 | MASIMO CORP | $2.7M | 0.2% | -50% | 47.1 | |
| 114 | INOVIO PHARMACEUTICALS, INC. | $2.6M | 0.1% | -51% | — | |
| 115 | TELEFLEX INC | $2.5M | 0.1% | -87% | 30.5 | |
| 116 | BRIGHT MINDS BIOSCIENCES INC. | $2.5M | 0.1% | +384% | — | |
| 117 | BioAge Labs, Inc. | $2.4M | 0.1% | -50% | 28.6 | |
| 118 | Alector, Inc. | $2.3M | 0.1% | -53% | 8.9 | |
| 119 | PFIZER INC | $2.2M | 0.1% | -47% | 69 | |
| 120 | DELCATH SYSTEMS, INC. | $2.1M | 0.1% | -50% | 54.9 | |
| 121 | BIOGEN INC. | $2.0M | 0.1% | -77% | 65.6 | |
| 122 | Connect Biopharma Holdings Ltd | $1.9M | 0.1% | NEW | — | |
| 123 | — | SPDR SERIES TRUST - STATE STREET SPD | $1.9M | — | NEW | — |
| 124 | Summit Therapeutics Inc. | $1.7M | 0.1% | -50% | — | |
| 125 | GLOBUS MEDICAL INC | $1.7M | 0.1% | -50% | 77.6 | |
| 126 | Alkermes plc. | $1.6M | 0.1% | -64% | — | |
| 127 | uniQure N.V. | $1.6M | — | +67% | — | |
| 128 | SOLENO THERAPEUTICS INC | $1.6M | 0.1% | -44% | 46.3 | |
| 129 | Cohen Circle Acquisition Corp. II | $1.6M | 0.1% | -50% | — | |
| 130 | ROCKET PHARMACEUTICALS, INC. | $1.5M | 0.1% | -55% | — | |
| 131 | SUPERNUS PHARMACEUTICALS, INC. | $1.5M | 0.1% | -50% | 45.3 | |
| 132 | Centessa Pharmaceuticals plc | $1.5M | 0.1% | -50% | — | |
| 133 | AMICUS THERAPEUTICS, INC. | $1.5M | 0.1% | NEW | 44.2 | |
| 134 | Maze Therapeutics, Inc. | $1.5M | 0.1% | -86% | 19.7 | |
| 135 | UNITEDHEALTH GROUP INC | $1.5M | 0.1% | NEW | 66.8 | |
| 136 | Adagio Medical Holdings, Inc. | $1.4M | 0.1% | -48% | — | |
| 137 | FORWARD AIR CORP | $1.3M | 0.1% | +47% | 52.4 | |
| 138 | SENSIENT TECHNOLOGIES CORP | $1.3M | 0.1% | NEW | 57.3 | |
| 139 | Kiniksa Pharmaceuticals International, plc | $1.3M | 0.1% | -53% | — | |
| 140 | Corvus Pharmaceuticals, Inc. | $1.3M | 0.1% | -91% | — | |
| 141 | Satellos Bioscience Inc. | $1.3M | 0.1% | NEW | — | |
| 142 | uniQure N.V. | $1.2M | 0.1% | -84% | — | |
| 143 | NOVO NORDISK A S | $1.2M | 0.1% | NEW | — | |
| 144 | ProMIS Neurosciences Inc. | $1.2M | 0.1% | NEW | — | |
| 145 | LEXICON PHARMACEUTICALS, INC. | $1.2M | 0.1% | NEW | 33.1 | |
| 146 | Schrodinger, Inc. | $1.2M | 0.1% | NEW | 31 | |
| 147 | Karyopharm Therapeutics Inc. | $1.1M | — | NEW | 20.4 | |
| 148 | Xencor Inc | $1.1M | 0.1% | -17% | 13.1 | |
| 149 | OmniAb, Inc. | $1.1M | 0.1% | -50% | 9.7 | |
| 150 | 4D Molecular Therapeutics, Inc. | $1.1M | 0.1% | -50% | 23.2 | |
| 151 | Keros Therapeutics, Inc. | $1.1M | 0.1% | +158% | 57.2 | |
| 152 | Day One Biopharmaceuticals, Inc. | $1.1M | 0.1% | NEW | 42.6 | |
| 153 | BRISTOL MYERS SQUIBB CO | $1.1M | 0.1% | -56% | 70.1 | |
| 154 | Tango Therapeutics, Inc. | $1.0M | 0.1% | -82% | 26.9 | |
| 155 | Tenaya Therapeutics, Inc. | $1.0M | 0.1% | -50% | — | |
| 156 | BEST SPAC I Acquisition Corp. | $1.0M | 0.1% | -50% | — | |
| 157 | MCKESSON CORP | $1.0M | 0.1% | -50% | 63.7 | |
| 158 | BIOMARIN PHARMACEUTICAL INC | $1.0M | 0.1% | -29% | 74.1 | |
| 159 | — | ARROWHEAD PHARMACEUTICALS IN - NOTE 1/1 | $1.0M | 0.1% | NEW | — |
| 160 | Oruka Therapeutics, Inc. | $1.0M | 0.1% | -50% | — | |
| 161 | ELECTRONIC ARTS INC. | $1.0M | 0.1% | -50% | 71.1 | |
| 162 | Fulcrum Therapeutics, Inc. | $1.0M | 0.1% | -95% | — | |
| 163 | BIOCRYST PHARMACEUTICALS INC | $999,600 | 0.1% | +17% | 37.2 | |
| 164 | Guardant Health, Inc. | $923,700 | 0.1% | -29% | 36.1 | |
| 165 | CRESCENT BIOPHARMA, INC. | $923,515 | 0.1% | -96% | 28 | |
| 166 | Context Therapeutics Inc. | $919,866 | 0.1% | -50% | — | |
| 167 | enGene Therapeutics Inc. | $910,402 | 0.1% | -78% | — | |
| 168 | Silence Therapeutics plc | $907,267 | 0.1% | +264% | — | |
| 169 | ALEXANDRIA REAL ESTATE EQUITIES, INC. | $905,190 | 0.1% | -40% | 45.1 | |
| 170 | Keen Vision Acquisition Corp. | $900,000 | — | -50% | — | |
| 171 | iBio, Inc. | $892,768 | 0.1% | -42% | — | |
| 172 | BioNTech SE | $888,800 | 0.1% | -50% | — | |
| 173 | GILEAD SCIENCES, INC. | $885,139 | 0.1% | -52% | 77.8 | |
| 174 | Nurix Therapeutics, Inc. | $869,085 | 0.1% | -61% | 13.2 | |
| 175 | Dyne Therapeutics, Inc. | $860,504 | 0.1% | -44% | — | |
| 176 | INTUITIVE SURGICAL INC | $843,612 | 0.1% | -10% | 81.4 | |
| 177 | Adlai Nortye Ltd. | $815,930 | 0.1% | NEW | — | |
| 178 | WW INTERNATIONAL, INC. | $792,798 | 0.1% | -49% | 26.4 | |
| 179 | Avidity Biosciences, Inc. | $771,000 | 0.1% | -95% | 22.3 | |
| 180 | Integer Holdings Corp | $770,000 | 0.1% | NEW | 50.2 | |
| 181 | Replimune Group, Inc. | $765,000 | — | +100% | — | |
| 182 | Karyopharm Therapeutics Inc. | $761,620 | 0.1% | +37% | 20.4 | |
| 183 | Compass Therapeutics, Inc. | $735,310 | 0.0% | -50% | — | |
| 184 | Nuvalent, Inc. | $711,208 | 0.0% | -49% | — | |
| 185 | Cullinan Therapeutics, Inc. | $710,500 | 0.0% | -50% | — | |
| 186 | IDEAYA Biosciences, Inc. | $666,400 | 0.0% | -50% | 10.5 | |
| 187 | FRACTYL HEALTH, INC. | $654,000 | — | -50% | — | |
| 188 | ENANTA PHARMACEUTICALS INC | $648,639 | 0.0% | -38% | 15.5 | |
| 189 | Vera Therapeutics, Inc. | $645,008 | 0.0% | -46% | — | |
| 190 | VYNE Therapeutics Inc. | $635,680 | 0.0% | +110% | — | |
| 191 | BOSTON SCIENTIFIC CORP | $627,500 | 0.0% | +0% | 79.9 | |
| 192 | Avantor, Inc. | $627,200 | 0.0% | -43% | 38.4 | |
| 193 | ARVINAS, INC. | $610,465 | 0.0% | -50% | 13.9 | |
| 194 | Kezar Life Sciences, Inc. | $607,943 | 0.0% | -65% | — | |
| 195 | Kalaris Therapeutics, Inc. | $577,000 | 0.0% | -50% | — | |
| 196 | Mirum Pharmaceuticals, Inc. | $572,756 | 0.0% | NEW | 32.7 | |
| 197 | Jazz Pharmaceuticals plc | $567,150 | 0.0% | -81% | — | |
| 198 | ASSEMBLY BIOSCIENCES, INC. | $553,529 | 0.0% | -49% | 26.6 | |
| 199 | Prelude Therapeutics Inc | $522,662 | 0.0% | NEW | 27 | |
| 200 | Globa Terra Acquisition Corp | $518,000 | 0.0% | -50% | — | |
| 201 | WisdomTree, Inc. | $503,400 | 0.0% | -50% | 62.9 | |
| 202 | Aclaris Therapeutics, Inc. | $496,598 | 0.0% | -89% | 9.2 | |
| 203 | Praxis Precision Medicines, Inc. | $483,285 | 0.0% | -50% | — | |
| 204 | Pulmonx Corp | $483,101 | 0.0% | -47% | 23.9 | |
| 205 | Elanco Animal Health Inc | $478,600 | 0.0% | -50% | 52.2 | |
| 206 | NOVO NORDISK A S | $477,750 | — | NEW | — | |
| 207 | Phathom Pharmaceuticals, Inc. | $476,619 | 0.0% | -50% | 32.5 | |
| 208 | MADRIGAL PHARMACEUTICALS, INC. | $468,506 | 0.0% | -50% | 25.4 | |
| 209 | PolyPid Ltd. | $455,301 | 0.0% | -50% | — | |
| 210 | Alibaba Group Holding Ltd | $448,896 | 0.0% | -50% | — | |
| 211 | Core Scientific, Inc./tx | $448,800 | 0.0% | -50% | 14 | |
| 212 | Whitehawk Therapeutics, Inc. | $443,335 | 0.0% | -17% | 9.6 | |
| 213 | Natera, Inc. | $429,379 | 0.0% | -50% | 46.4 | |
| 214 | Vistagen Therapeutics, Inc. | $429,277 | 0.0% | -40% | — | |
| 215 | TherapeuticsMD, Inc. | $422,604 | 0.0% | -50% | — | |
| 216 | Ultragenyx Pharmaceutical Inc. | $419,000 | — | +0% | 31 | |
| 217 | Syndax Pharmaceuticals Inc | $408,800 | 0.0% | -27% | 30 | |
| 218 | Tectonic Therapeutic, Inc. | $401,861 | 0.0% | -78% | — | |
| 219 | Entrada Therapeutics, Inc. | $384,910 | 0.0% | NEW | 8.5 | |
| 220 | Biohaven Ltd. | $378,813 | 0.0% | -35% | — | |
| 221 | Merck & Co., Inc. | $377,711 | 0.0% | -84% | 70.9 | |
| 222 | Verastem, Inc. | $376,830 | 0.0% | NEW | 40.8 | |
| 223 | MoonLake Immunotherapeutics | $372,800 | — | NEW | — | |
| 224 | REGENXBIO Inc. | $372,206 | 0.0% | -85% | 26.9 | |
| 225 | Adicet Bio, Inc. | $366,562 | 0.0% | -79% | — | |
| 226 | Legend Biotech Corp | $361,800 | 0.0% | NEW | 44.2 | |
| 227 | Surrozen, Inc./DE | $349,560 | 0.0% | NEW | — | |
| 228 | Zentalis Pharmaceuticals, Inc. | $338,448 | 0.0% | -10% | — | |
| 229 | BICYCLE THERAPEUTICS PLC | $330,823 | 0.0% | NEW | — | |
| 230 | NEUROCRINE BIOSCIENCES INC | $329,350 | 0.0% | NEW | 75.4 | |
| 231 | Corbus Pharmaceuticals Holdings, Inc. | $328,650 | — | NEW | — | |
| 232 | Wave Life Sciences Ltd. | $325,525 | 0.0% | NEW | — | |
| 233 | Kura Oncology, Inc. | $325,200 | 0.0% | -50% | 9.1 | |
| 234 | KIORA PHARMACEUTICALS INC | $324,126 | 0.0% | -50% | — | |
| 235 | CORCEPT THERAPEUTICS INC | $322,480 | 0.0% | NEW | 55.4 | |
| 236 | Upstream Bio, Inc. | $315,000 | 0.0% | NEW | 22.6 | |
| 237 | ORTHOPEDIATRICS CORP | $314,940 | 0.0% | -50% | 33.4 | |
| 238 | Annexon, Inc. | $304,700 | 0.0% | -43% | — | |
| 239 | GERON CORP | $298,000 | 0.0% | -70% | — | |
| 240 | JD.com, Inc. | $295,700 | 0.0% | -50% | — | |
| 241 | PMV Pharmaceuticals, Inc. | $286,450 | 0.0% | +14% | — | |
| 242 | Traws Pharma, Inc. | $281,999 | 0.0% | -50% | — | |
| 243 | Jade Biosciences, Inc. | $281,000 | 0.0% | -52% | — | |
| 244 | Ultragenyx Pharmaceutical Inc. | $280,730 | 0.0% | NEW | 31 | |
| 245 | ProCap Acquisition Corp | $278,560 | 0.0% | -50% | — | |
| 246 | Bicara Therapeutics Inc. | $272,592 | 0.0% | -50% | — | |
| 247 | RxSight, Inc. | $266,420 | 0.0% | -1% | 32 | |
| 248 | Palo Alto Networks Inc | $256,512 | 0.0% | NEW | 66.5 | |
| 249 | Intellia Therapeutics, Inc. | $250,208 | 0.0% | NEW | 24.5 | |
| 250 | CrowdStrike Holdings, Inc. | $249,862 | 0.0% | NEW | 55 | |
| 251 | Rubrik, Inc. | $239,953 | 0.0% | NEW | 49.5 | |
| 252 | Royalty Pharma plc | $239,850 | 0.0% | NEW | — | |
| 253 | Surgery Partners, Inc. | $238,400 | 0.0% | -50% | 48 | |
| 254 | Larimar Therapeutics, Inc. | $237,353 | 0.0% | -86% | — | |
| 255 | Evolus, Inc. | $229,580 | 0.0% | -22% | 30 | |
| 256 | Q32 Bio Inc. | $224,700 | 0.0% | -13% | 23.1 | |
| 257 | Longeveron Inc. | $208,000 | 0.0% | NEW | — | |
| 258 | ANAPTYSBIO, INC | $205,091 | 0.0% | NEW | 29.4 | |
| 259 | — | CANTOR EQUITY PARTNERS VI IN - CL A ORD SHS | $202,000 | 0.0% | NEW | — |
| 260 | KalVista Pharmaceuticals, Inc. | $201,300 | 0.0% | -50% | 25.9 | |
| 261 | Kyverna Therapeutics, Inc. | $193,554 | 0.0% | -80% | — | |
| 262 | Nuvation Bio Inc. | $186,615 | 0.0% | NEW | 29.5 | |
| 263 | Benitec Biopharma Inc. | $186,375 | 0.0% | NEW | — | |
| 264 | Lipocine Inc. | $185,208 | 0.0% | NEW | — | |
| 265 | Rallybio Corp | $184,199 | 0.0% | NEW | — | |
| 266 | Rezolute, Inc. | $178,971 | 0.0% | -24% | — | |
| 267 | Q/C TECHNOLOGIES, INC. | $172,500 | 0.0% | NEW | — | |
| 268 | Erasca, Inc. | $161,800 | 0.0% | NEW | — | |
| 269 | Coya Therapeutics, Inc. | $161,146 | 0.0% | NEW | — | |
| 270 | Personalis, Inc. | $159,250 | 0.0% | NEW | 15.7 | |
| 271 | SI-BONE, Inc. | $158,885 | 0.0% | NEW | 37.7 | |
| 272 | Oncology Institute, Inc. | $153,500 | 0.0% | NEW | 37.8 | |
| 273 | CYBIN INC. | $150,134 | 0.0% | -93% | — | |
| 274 | Neuronetics, Inc. | $145,000 | 0.0% | NEW | 31.3 | |
| 275 | ARDELYX, INC. | $143,161 | 0.0% | NEW | 35.3 | |
| 276 | InflaRx N.V. | $141,558 | 0.0% | NEW | — | |
| 277 | ACHIEVE LIFE SCIENCES, INC. | $140,532 | 0.0% | -50% | — | |
| 278 | Voyager Therapeutics, Inc. | $135,100 | 0.0% | -50% | 5.5 | |
| 279 | Chemomab Therapeutics Ltd. | $125,600 | 0.0% | -50% | — | |
| 280 | Jasper Therapeutics, Inc. | $122,668 | 0.0% | -50% | — | |
| 281 | Neuphoria Therapeutics Inc. | $122,100 | 0.0% | -50% | — | |
| 282 | Milestone Pharmaceuticals Inc. | $119,000 | 0.0% | -50% | — | |
| 283 | Arcturus Therapeutics Holdings Inc. | $115,800 | 0.0% | NEW | 12 | |
| 284 | MACROGENICS INC | $115,600 | 0.0% | NEW | 31.7 | |
| 285 | C4 Therapeutics, Inc. | $113,090 | 0.0% | NEW | 6.5 | |
| 286 | RECURSION PHARMACEUTICALS, INC. | $107,450 | 0.0% | -50% | 13.6 | |
| 287 | Design Therapeutics, Inc. | $106,400 | 0.0% | NEW | — | |
| 288 | Gossamer Bio, Inc. | $94,454 | 0.0% | -32% | 27.1 | |
| 289 | Immix Biopharma, Inc. | $91,100 | 0.0% | -90% | — | |
| 290 | Solidion Technology Inc. | $85,185 | — | -50% | — | |
| 291 | Lite Strategy, Inc. | $78,059 | 0.0% | -50% | — | |
| 292 | VERU INC. | $77,350 | 0.0% | -50% | — | |
| 293 | KYNTRA BIO, INC. | $70,980 | 0.0% | -50% | 60.7 | |
| 294 | CLOVER HEALTH INVESTMENTS, CORP. /DE | $70,400 | 0.0% | -59% | 55 | |
| 295 | Biomea Fusion, Inc. | $66,433 | 0.0% | -50% | — | |
| 296 | Neumora Therapeutics, Inc. | $64,545 | 0.0% | -67% | — | |
| 297 | Organon & Co. | $59,900 | 0.0% | -86% | 55.1 | |
| 298 | Esperion Therapeutics, Inc. | $58,636 | 0.0% | NEW | 34.3 | |
| 299 | Mereo BioPharma Group plc | $49,500 | 0.0% | -50% | — | |
| 300 | AN2 Therapeutics, Inc. | $47,405 | 0.0% | NEW | — | |
| 301 | — | A SPAC III ACQUISITION CORP - RIGHT 01/02/2026 | $42,441 | 0.0% | -50% | — |
| 302 | Aquestive Therapeutics, Inc. | $41,500 | 0.0% | NEW | 11.7 | |
| 303 | aTYR PHARMA INC | $39,534 | 0.0% | -50% | — | |
| 304 | BioAtla, Inc. | $36,725 | 0.0% | -38% | — | |
| 305 | KALA BIO, Inc. | $24,490 | 0.0% | -50% | — | |
| 306 | Coherus Oncology, Inc. | $17,519 | 0.0% | -50% | 42.9 | |
| 307 | ProQR Therapeutics N.V. | $16,200 | 0.0% | -50% | — | |
| 308 | Quince Therapeutics, Inc. | $5,080 | 0.0% | -42% | — | |
| 309 | Quince Therapeutics, Inc. | $5,070 | — | -69% | — | |
| 310 | IMMUNIC, INC. | $0 | 0.0% | NEW | — |
New Positions (78)
Exited Positions (40)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ADAR1 Capital Management, LLC including:
Track ADAR1 Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ADAR1 Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ADAR1 Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ADAR1 Capital Management, LLC (SEC CIK: 1940272), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ADAR1 Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.